TitleProduct

Avelumab

  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Shanghai

  • Validity to:

    Long-term effective

  • Last update:

    2018-07-27 08:19

  • Browse the number:

    373

Send an inquiries
+
Shanghai TheraMabs Bio-Technology Co.,Ltd
Contactaixin:

saimai2018(Mr.)  

Email:

sales@theramabs.com

telephone:

+86-21-58582603

phone:

13611999090

Arrea:

Shanghai

Address:

Room 156, 133# Dongzheng Road, Pudong Disrict, Shanghai, China

Website:

http://www.therapeuticmab.com/ http://saimai2018.chinamerchants-logistics.com/

+

This product is the biosimilar of Avelumab (1537032-82-8), which is a programmed death ligand-1 (PD-L1) blocking antibody. The biosimilar is a human IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa, which is produced by recombinant DNA technology in Chinese Hamster Ovary cell expression system and is purified by a process that includes specific viral inactivation and removal steps.


Features and Advantages:

Name

Biosimilar of Avelumab

CAS NO.

1537032-82-8

Type

Whole antibody

Source

Human

Target

PD-L1

Clone

Monoclone

Molecular Weight

147 kDa

Antibody Form

Purified immunoglobulin

Physical Form

Solution

Place of Origin

China (Mainland)

Storage

Sealed and stored at -70±15℃, away from light


Specifications:

The biosimilar of Avelumab is supplied at a concentration of 20 mg/mL in the same buffer system with original drug (BAVENCIO) as a sterile, clear and colorless, preservative-free solution. In addition, our company also provides customized services according to customers' needs.

Annual production of the biosimilar of Avelumab stock is 80~150kgs, in addition, our company also provides small packaging (1g) for customers to evaluate product quality, for more information please contact us.


Applications:

Avelumab, the trade name BAVENCIO, is a pharmaceutical drug for use in immunotherapy, for the treatment of non-small-cell lung carcinoma (NSCLC), gastric cancer, Merkel-cell carcinoma. 

The formulation and filling of the biosimilar of Avelumab is carried out under cGMP conditions as defined by the worldwide regulatory agencies including US FDA, EMA, CFDA. T Our products are only used in scientific research and are strictly prohibited for clinical and commercial use before approve by FDA.


http://www.therapeuticmab.com/